This section contains press releases and other materials from third parties (including paid content). The Globe and Mail has not reviewed this content. Please see disclaimer.

Analysts Offer Insights on Healthcare Companies: Alcon (ALC), Senseonics Holdings (SENS) and Dianthus Therapeutics (DNTH)

Tipranks - Tipranks - Thu May 7, 12:44AM CDT

There’s a lot to be optimistic about in the Healthcare sector as 3 analysts just weighed in on Alcon (ALC), Senseonics Holdings (SENS) and Dianthus Therapeutics (DNTH) with bullish sentiments.

Claim 55% Off TipRanks

Alcon (ALC)

In a report released yesterday, David Saxon from Needham reiterated a Buy rating on Alcon, with a price target of $100.00. The company’s shares closed last Tuesday at $74.45.

According to TipRanks.com, Saxon is a 1-star analyst with an average return of -1.7% and a 32.4% success rate. Saxon covers the Healthcare sector, focusing on stocks such as Bausch + Lomb Corporation, Irhythm Technologies, and Alphatec Holdings. ;'>

The word on The Street in general, suggests a Moderate Buy analyst consensus rating for Alcon with a $96.73 average price target, a 30.6% upside from current levels. In a report issued on April 24, TipRanks – PerPlexity also upgraded the stock to Buy with a CHF71.00 price target.

See the top stocks recommended by analysts >>

Senseonics Holdings (SENS)

TD Cowen analyst Josh Jennings maintained a Buy rating on Senseonics Holdings yesterday and set a price target of $15.00. The company’s shares closed last Tuesday at $5.00.

According to TipRanks.com, Jennings is a 2-star analyst with an average return of 0.0% and a 43.1% success rate. Jennings covers the Healthcare sector, focusing on stocks such as Anteris Technologies Global Corp., Establishment Labs Holdings, and Orchestra BioMed Holdings. ;'>

The word on The Street in general, suggests a Moderate Buy analyst consensus rating for Senseonics Holdings with a $18.92 average price target, a 277.6% upside from current levels. In a report issued on April 24, Lake Street also maintained a Buy rating on the stock with a $20.00 price target.

Dianthus Therapeutics (DNTH)

TD Cowen analyst Yaron Werber maintained a Buy rating on Dianthus Therapeutics today. The company’s shares closed last Tuesday at $90.24.

According to TipRanks.com, Werber is a 5-star analyst with an average return of 25.1% and a 60.0% success rate. Werber covers the Healthcare sector, focusing on stocks such as Ultragenyx Pharmaceutical, Terns Pharmaceuticals, and Ionis Pharmaceuticals. ;'>

The word on The Street in general, suggests a Strong Buy analyst consensus rating for Dianthus Therapeutics with a $125.15 average price target, which is a 38.2% upside from current levels. In a report issued on April 21, TipRanks – Google also upgraded the stock to Buy with a $104.00 price target.

Read More on ALC:

Disclaimer & DisclosureReport an Issue

This article contains syndicated content. We have not reviewed, approved, or endorsed the content, and may receive compensation for placement of the content on this site. For more information please view the Barchart Disclosure Policy here.

All market data (will open in new tab) is provided by Barchart Solutions. Copyright © 2026.

Information is provided 'as is' and solely for informational purposes, not for trading purposes or advice. For exchange delays and terms of use, please read disclaimer (will open in new tab).